1. Medtech Insight
  2. >>Archive

US Markets for Nonvascular Stents

Lately, drug-eluting stents have downright monopolized all discussions of new stent technology, but there's a whole world of stenting outside of the interventional cardiology suite, and some of these clinical applications represent healthy markets for small companies. According to a report published in June by the Medtech Insight division of Windhover Information, "US Markets for Nonvascular Stents," sales of stents in several non-cardiology niche markets totaled approximately $152 million in 2005, a year in which stents were used in approximately 491,000 nonvascular endoluminal recanalization procedures. Overall, sales of these products are expected to grow at an annual compound rate of almost 3%, reaching approximately $174 million in the year 2010.

Lately, drug-eluting stents have downright monopolized all discussions of new stent technology, but there's a whole world of stenting outside of the interventional cardiology suite, and some of these clinical applications represent healthy markets for small companies. According to a report published in June by the Medtech Insight division of Windhover Information, "US Markets for Nonvascular Stents," sales of stents in several non-cardiology niche markets totaled approximately $152 million in 2005, a year in which stents were used in approximately 491,000 nonvascular endoluminal recanalization procedures. Overall, sales of these products are expected to grow at an annual compound rate of almost 3%, reaching approximately $174 million in the year 2010.

In gastroenterology, pulmonology, and urology, stents are essentially used for the same reasons that they're used in cardiovascular and peripheral vascular disease. They function as endoluminal scaffolds in the recanalization...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.